Get the Stockscreener App
57.18
0.47%
0.27
After Hours:
57.19
0.010
+0.02%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $57.18, with a volume of 27.55M.
It is up +0.47% in the last 24 hours and down -0.71% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$56.91
Open:
$57
24h Volume:
27.55M
Relative Volume:
2.38
Market Cap:
$116.77B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
16.05
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-3.83%
1M Performance:
-0.71%
6M Performance:
+16.22%
1Y Performance:
+19.50%
1-Day Range:
$56.53
$57.33
1-Week Range:
$56.26
$59.78
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.18 | 116.21B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach - Fierce Biotech
BioNTech and Bristol Myers Squibb Announce Promising Interim Data for Pumitamig Combined with Chemotherapy in First-Line Non-Small Cell Lung Cancer at ASCO 2026 - Quiver Quantitative
Experimental BioNTech lung cancer drug shows high responses in early trial - Stock Titan
Bristol-Myers Squibb Company stock (US0897961004): ASCO 2026 mezigdomide data in focus after Phase 3 - AD HOC NEWS
Positive Data for Mezigdomide Boosts Bristol Myers Squibb (BMY) and C4 Therapeutics (C FOUR) - GuruFocus
Bristol Myers unveils data for one of its next-gen blood cancer drugs - BioPharma Dive
Texas comptroller recommends Bristol Myers Squibb's $1B manufacturing plant for tax break - KHOU
ASCO: BMS’s Mezigdomide More Than Doubles PFS In Relapsed/Refractory Myeloma - Citeline News & Insights
ASCO: BMS hails "compelling" phase 3 celmod readout - pharmaphorum
Bristol Myers Squibb (BMY) Reports Positive Results for Mezigdom - GuruFocus
5 must-read innovation headlines: Pharma giant considers Houston hub + more - InnovationMap
Bristol Myers drug delays myeloma progression in hard to treat patients - Reuters
BMY: New Insights from Bristol Myers Squibb's Phase 3 Cancer Tri - GuruFocus
BMS-Hengrui deal strikes panic in Washington - BioWorld News
Experimental Bristol Myers pill delays myeloma worsening about 10 months - Stock Titan
SBI Okasan Asset Management Co.Ltd. Takes $1.19 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $61 - Moomoo
Ilmarinen Mutual Pension Insurance Co Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Partners with Anthropic - Insider Monkey
Bristol Myers Squibb stock (US1101221083): steady NYSE pricing ahead of next catalysts - AD HOC NEWS
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
UBS reiterates Bristol-Myers Squibb stock rating on pipeline potential - Investing.com
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
BMO Capital Maintains Market Perform Rating on Bristol-Myers (BMY) After Earnings Beat - Insider Monkey
Flputnam Investment Management Co. Increases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co stock (US1101221083): pharma heavyweight after Q1 2026 earnings and dividend - AD HOC NEWS
Hengrui, BMS deal watershed moment for China biotech - BioWorld News
Bristol-Myers Squibb stock (US1078421011): oncology and immunology pipeline under investor scrutiny - AD HOC NEWS
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol-Myers Squibb Company stock (US0897961004): Pharma heavyweight navigates Revlimid cliff and w - AD HOC NEWS
Bristol-Myers Squibb (BMY) Stock Analysis: Evaluating Its 5.89% Upside Potential - DirectorsTalk Interviews
Bristol-Myers Squibb Company stock (US0897961004): cancer pipeline focus after Opdivo and Eliquis up - AD HOC NEWS
Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds? - Insider Monkey
12 Best Dividend Stocks to Invest In According to Hedge Funds - Insider Monkey
Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First. - Yahoo Finance
Bristol Myers Squibb Company $BMY Position Trimmed by Associated Banc Corp - MarketBeat
How Bristol Myers Squibb’s Claude AI Deployment Across its Pipeline (BMY) Has Changed Its Investment Story - simplywall.st
Meiji Yasuda Asset Management Co Ltd. Purchases 55,355 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership - Insider Monkey
Bristol-Myers Squibb Company stock (US0897961004): Analyst moves and dividend draw fresh attention - AD HOC NEWS
BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung - GlobeNewswire Inc.
Bristol Myers Squibb Company $BMY Stock Holdings Increased by ABN Amro Investment Solutions - MarketBeat
Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof. - TIKR.com
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - BioSpace
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientif - pharmiweb.com
HALL CAPITAL MANAGEMENT CO INC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Bristol-Myers Squibb Company Stocks - TradingView
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid - BioPharma Dive
Bristol Myers Squibb Partners With Anthropic to Deploy Claude Across Global Operations - Digital Health News
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):